These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10768625)

  • 21. Pooled analysis of tobacco use and risk of Parkinson disease.
    Ritz B; Ascherio A; Checkoway H; Marder KS; Nelson LM; Rocca WA; Ross GW; Strickland D; Van Den Eeden SK; Gorell J
    Arch Neurol; 2007 Jul; 64(7):990-7. PubMed ID: 17620489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of Parkinson's disease in the Faroe Islands.
    Wermuth L; Joensen P; Bünger N; Jeune B
    Neurology; 1997 Aug; 49(2):426-32. PubMed ID: 9270572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.
    Hely MA; Morris JG; Traficante R; Reid WG; O'Sullivan DJ; Williamson PM
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):300-7. PubMed ID: 10449550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causes of death in a community-based study of Parkinson's disease.
    Beyer MK; Herlofson K; Arsland D; Larsen JP
    Acta Neurol Scand; 2001 Jan; 103(1):7-11. PubMed ID: 11153892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease in Taiwan: an analysis of 215 patients.
    Chia LG; Liu LH
    Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls.
    Tan EK; Lum SY; Fook-Chong SM; Teoh ML; Yih Y; Tan L; Tan A; Wong MC
    Neurology; 2002 Feb; 58(3):465-8. PubMed ID: 11839852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality from Parkinson's disease in China: Findings from a five-year follow up study in Shanghai.
    Wang G; Li XJ; Hu YS; Cheng Q; Wang CF; Xiao Q; Liu J; Ma JF; Zhou HY; Pan J; Tan YY; Wang Y; Chen SD
    Can J Neurol Sci; 2015 Jul; 42(4):242-7. PubMed ID: 26153040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa in Parkinson disease: a long-term appraisal of mortality.
    Joseph C; Chassan JB; Koch ML
    Ann Neurol; 1978 Feb; 3(2):116-8. PubMed ID: 418738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
    Folkestad L
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients.
    Shoval G; Stubbs B; Balicer RD; Feldman B; Hoshen M; Zalsman G; Sagy R; Hochman E; Weizman A; Krivoy A
    Parkinsonism Relat Disord; 2017 Oct; 43():92-96. PubMed ID: 28797565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.
    Savica R; Grossardt BR; Bower JH; Ahlskog JE; Boeve BF; Graff-Radford J; Rocca WA; Mielke MM
    JAMA Neurol; 2017 Jul; 74(7):839-846. PubMed ID: 28505261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years].
    Rufino JM; García C; Vega N; Macía M; Hernández D; Rodríguez A; Maceira B; Lorenzo V
    Nefrologia; 2011; 31(2):174-84. PubMed ID: 21461011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
    Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
    Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What predicts mortality in Parkinson disease?: a prospective population-based long-term study.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Alves G
    Neurology; 2010 Oct; 75(14):1270-6. PubMed ID: 20921512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
    Biglan KM; Holloway RG; McDermott MP; Richard IH;
    Neurology; 2007 Jul; 69(2):187-95. PubMed ID: 17620552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect.
    Järvelä JT; Rinne JO; Eskola O; Kaasinen V
    Parkinsonism Relat Disord; 2014 Aug; 20(8):894-7. PubMed ID: 24928032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyneuropathy in levodopa-treated Parkinson's patients.
    Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
    J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.